Savara Inc. (NASDAQ:SVRA) Receives Average Recommendation of “Moderate Buy” from Analysts

Savara Inc. (NASDAQ:SVRA) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $8.8571.

Several brokerages recently issued reports on SVRA. UBS Group set a $10.00 price objective on Savara in a research note on Tuesday, December 23rd. HC Wainwright increased their price target on shares of Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Tuesday, December 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a report on Thursday, January 22nd. Wells Fargo & Company upped their price objective on shares of Savara from $7.00 to $9.00 and gave the company an “overweight” rating in a research note on Thursday, December 18th. Finally, Citizens Jmp decreased their target price on shares of Savara from $11.00 to $10.00 and set a “market outperform” rating for the company in a research note on Thursday, November 13th.

Hedge Funds Weigh In On Savara

Several institutional investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. raised its holdings in Savara by 48.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock worth $60,000 after acquiring an additional 3,205 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Savara by 930.5% in the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after purchasing an additional 9,463 shares during the period. Xponance LLC bought a new position in shares of Savara in the fourth quarter worth about $66,000. CIBC Bancorp USA Inc. acquired a new position in shares of Savara during the 3rd quarter worth about $44,000. Finally, Prudential Financial Inc. bought a new stake in Savara during the 2nd quarter valued at approximately $30,000. 87.93% of the stock is currently owned by institutional investors.

Savara Stock Performance

Shares of SVRA opened at $6.02 on Monday. The company has a debt-to-equity ratio of 0.32, a current ratio of 7.65 and a quick ratio of 7.65. The stock has a market capitalization of $1.22 billion, a P/E ratio of -11.36 and a beta of 0.31. Savara has a 12-month low of $1.89 and a 12-month high of $7.01. The firm’s 50 day moving average is $5.81 and its 200-day moving average is $4.80.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.